pneumonia
Conditions
Interventions
Sulbactam / Ampicillin 1.5g, intravenous drip infusion within 1 hour before bronchoscopy, then Augmentin Combination Tablets (Potassium Clavulanate, Amoxicillin Hydrate) 750 mg, Amoxicillin Hydrate 75
Sponsors
Tokai University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Trans-bronchial tumor biopsy for the diagnosis of lung cancer is scheduled 2. High risk patient for post-bronchoscopy pneumonia; two or more factors among "age 70 years or older", "current smoker", "presence of central lesion on chest CT scan" are positive 3. Written informed consent has been obtained
Exclusion criteria
Exclusion criteria: 1. Presence of active infection at bronchoscopy 2. Body temperature 37 degree Celcius or higher at bronchoscopy 3. History of antibiotic therapy within 2 weeks prior to bronchoscopy 4. History of drug allergy to beta-lactam antibiotics 5. Presence of severe renal dysfunction with eGFR less than 10 mL/min 6. Other reasons which researchers consider inadequate to include in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prevalence of post-bronchoscopy pneumonia in the cases treated with prophylactic antibiotics | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Proportion of unexpected changes in the treatment of lung cancer within 30 days after bronchoscopy in the cases treated with prophylactic antibiotics 2. Prevalence of post-bronchoscopy pneumonia in the cases who failed to receive the scheduled treatment with prophylactic antibiotics 3. Prevalence of adverse effects of prophylactic antibiotic treatment 4. Risk factors of post-bronchoscopy pneumonia 5. Prevalence of post-bronchoscopy pneumonia in the cases treated with prophylactic antibiotics, excluding the cases examined with endobronchial ultrasonography-guide sheath method | — |
Countries
Japan
Contacts
Public ContactNaoki Hayama
Tokai University School of Medicine Division of Pulmonary Medicine, Department of Medicine
Outcome results
None listed